Pharmaceutical

Medigene and EpimAb to develop T cell engagers for solid tumours

Medigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell engagers (TCR-TCEs).

Mar 1, 2025 - 06:00
Medigene and EpimAb to develop T cell engagers for solid tumours
Medigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell engagers (TCR-TCEs).
Read the original article

Tags:

Previous Article

Rare disease treatments skipping UK patients largely due to costs, survey shows

Next Article

Why pharma is still far from a treatment for galactosemia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Risk adjusted net present value: What is the current va...

Dec 13, 2024

STAT+: Hospitals are not crumbling, Medicare experts tell Congress

STAT+: Hospitals are not crumbling, Medicare experts te...

Mar 20, 2023

Getting rid of bias in clinical calculators isn’t as simple as taking race out of the equation

Getting rid of bias in clinical calculators isn’t as si...

Jun 16, 2023